Cargando…
Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer
BACKGROUND: Surveillance programmes for women at increased genetic risk of breast cancer are being established worldwide but little is known of their efficacy in early detection of cancers and hence reduction in mortality. METHODS: Data were contributed from seven centres participating in the EU Dem...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851417/ https://www.ncbi.nlm.nih.gov/pubmed/10595275 http://dx.doi.org/10.1155/1999/805420 |
_version_ | 1782294278766067712 |
---|---|
author | Møller, Pål Reis, Marta M. Evans, Gareth Vasen, Hans Haites, Neva Anderson, Elaine Steel, C. Michael Apold, Jaran Lalloo, Fiona Mæhle, Lovise Preece, Paul Gregory, Helen Heimdal, Ketil European Familial Breast Cancer Collaborative Group, |
author_facet | Møller, Pål Reis, Marta M. Evans, Gareth Vasen, Hans Haites, Neva Anderson, Elaine Steel, C. Michael Apold, Jaran Lalloo, Fiona Mæhle, Lovise Preece, Paul Gregory, Helen Heimdal, Ketil European Familial Breast Cancer Collaborative Group, |
author_sort | Møller, Pål |
collection | PubMed |
description | BACKGROUND: Surveillance programmes for women at increased genetic risk of breast cancer are being established worldwide but little is known of their efficacy in early detection of cancers and hence reduction in mortality. METHODS: Data were contributed from seven centres participating in the EU Demonstration Programme on Clinical Services for Familial Breast Cancer. All breast tumours (n = 161) detected prospectively, from the time of enrolment of women in a screening programme, were recorded. Analysis took account of age at diagnosis, whether tumours were screen-detected or not, their pathological stage and outcome by Kaplan—Meier survival plots. RESULTS: Mean age at diagnosis was 48.6 years. Overall, 75% of tumours were detected in the course of planned examinations. For women under age 50 at diagnosis, this figure was 68%. Eighteen percent were mammographically negative, (23% in patients under age 50). At first (“prevalence”) round and at follow-up screening, 16% and 22% of tumours respectively were carcinoma in situ (CIS) while 27% and 22% respectively had evidence of nodal or distant spread (CaN+). Comparison of screen-detected and other tumours showed that the latter were more frequently mammogram-negative and CaN+. Overall five-year survival was 89% and five-year event-free survival 86%. Five-year event-free survival was 100% for CIS, 88% for invasive cancer without nodal or distant spread and 67% for CaN+. CONCLUSIONS: The majority of cancers arising in women at increased genetic risk of breast cancer can be detected by planned screening, even in those under age 50. Surveillance should include regular expert clinical examination and teaching of “breast awareness” as well as mammography. Attention to the logistics of screening programmes may improve still further the proportion of tumours that are screen-detected. The trend towards earlier pathological stage in tumours detected during follow-up rounds and the preliminary findings on survival analysis suggest that this approach will prove to be of long-term benefit for breast cancer families. |
format | Online Article Text |
id | pubmed-3851417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38514172013-12-18 Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer Møller, Pål Reis, Marta M. Evans, Gareth Vasen, Hans Haites, Neva Anderson, Elaine Steel, C. Michael Apold, Jaran Lalloo, Fiona Mæhle, Lovise Preece, Paul Gregory, Helen Heimdal, Ketil European Familial Breast Cancer Collaborative Group, Dis Markers Other BACKGROUND: Surveillance programmes for women at increased genetic risk of breast cancer are being established worldwide but little is known of their efficacy in early detection of cancers and hence reduction in mortality. METHODS: Data were contributed from seven centres participating in the EU Demonstration Programme on Clinical Services for Familial Breast Cancer. All breast tumours (n = 161) detected prospectively, from the time of enrolment of women in a screening programme, were recorded. Analysis took account of age at diagnosis, whether tumours were screen-detected or not, their pathological stage and outcome by Kaplan—Meier survival plots. RESULTS: Mean age at diagnosis was 48.6 years. Overall, 75% of tumours were detected in the course of planned examinations. For women under age 50 at diagnosis, this figure was 68%. Eighteen percent were mammographically negative, (23% in patients under age 50). At first (“prevalence”) round and at follow-up screening, 16% and 22% of tumours respectively were carcinoma in situ (CIS) while 27% and 22% respectively had evidence of nodal or distant spread (CaN+). Comparison of screen-detected and other tumours showed that the latter were more frequently mammogram-negative and CaN+. Overall five-year survival was 89% and five-year event-free survival 86%. Five-year event-free survival was 100% for CIS, 88% for invasive cancer without nodal or distant spread and 67% for CaN+. CONCLUSIONS: The majority of cancers arising in women at increased genetic risk of breast cancer can be detected by planned screening, even in those under age 50. Surveillance should include regular expert clinical examination and teaching of “breast awareness” as well as mammography. Attention to the logistics of screening programmes may improve still further the proportion of tumours that are screen-detected. The trend towards earlier pathological stage in tumours detected during follow-up rounds and the preliminary findings on survival analysis suggest that this approach will prove to be of long-term benefit for breast cancer families. IOS Press 1999 2002-06-07 /pmc/articles/PMC3851417/ /pubmed/10595275 http://dx.doi.org/10.1155/1999/805420 Text en Copyright © 1999 Hindawi Publishing Corporation. |
spellingShingle | Other Møller, Pål Reis, Marta M. Evans, Gareth Vasen, Hans Haites, Neva Anderson, Elaine Steel, C. Michael Apold, Jaran Lalloo, Fiona Mæhle, Lovise Preece, Paul Gregory, Helen Heimdal, Ketil European Familial Breast Cancer Collaborative Group, Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer |
title | Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer |
title_full | Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer |
title_fullStr | Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer |
title_full_unstemmed | Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer |
title_short | Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer |
title_sort | efficacy of early diagnosis and treatment in women with a family history of breast cancer |
topic | Other |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851417/ https://www.ncbi.nlm.nih.gov/pubmed/10595275 http://dx.doi.org/10.1155/1999/805420 |
work_keys_str_mv | AT møllerpal efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT reismartam efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT evansgareth efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT vasenhans efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT haitesneva efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT andersonelaine efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT steelcmichael efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT apoldjaran efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT lalloofiona efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT mæhlelovise efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT preecepaul efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT gregoryhelen efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT heimdalketil efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer AT europeanfamilialbreastcancercollaborativegroup efficacyofearlydiagnosisandtreatmentinwomenwithafamilyhistoryofbreastcancer |